ceftazidime/NXL104 + metronidazole + meropenem
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Complicated Intra-abdominal Infections
Conditions
Complicated Intra-abdominal Infections
Trial Timeline
Mar 31, 2009 → Dec 31, 2009
NCT ID
NCT00752219About ceftazidime/NXL104 + metronidazole + meropenem
ceftazidime/NXL104 + metronidazole + meropenem is a phase 2 stage product being developed by Pfizer for Complicated Intra-abdominal Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT00752219. Target conditions include Complicated Intra-abdominal Infections.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00752219 | Phase 2 | Completed |
Competing Products
20 competing products in Complicated Intra-abdominal Infections